179 related articles for article (PubMed ID: 12839283)
1. Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents.
Frost BM; Lönnerholm G; Koopmans P; Abrahamsson J; Behrendtz M; Castor A; Forestier E; Uges DR; de Graaf SS
Acta Paediatr; 2003 May; 92(5):551-7. PubMed ID: 12839283
[TBL] [Abstract][Full Text] [Related]
2. Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG).
Groninger E; Meeuwsen-de Boer T; Koopmans P; Uges D; Sluiter W; Veerman A; Kamps W; de Graaf S
Eur J Cancer; 2005 Jan; 41(1):98-103. PubMed ID: 15617994
[TBL] [Abstract][Full Text] [Related]
3. Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia.
Lönnerholm G; Frost BM; Abrahamsson J; Behrendtz M; Castor A; Forestier E; Heyman M; Uges DR; de Graaf SS
Br J Haematol; 2008 Aug; 142(4):616-21. PubMed ID: 18537965
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia.
Groninger E; Meeuwsen-de Boar T; Koopmans P; Uges D; Sluiter W; Veerman A; Kamps W; de Graaf S
Pediatr Res; 2002 Jul; 52(1):113-8. PubMed ID: 12084857
[TBL] [Abstract][Full Text] [Related]
5. Vincristine pharmacokinetics after repetitive dosing in children.
Gidding CE; Meeuwsen-de Boer GJ; Koopmans P; Uges DR; Kamps WA; de Graaf SS
Cancer Chemother Pharmacol; 1999; 44(3):203-9. PubMed ID: 10453721
[TBL] [Abstract][Full Text] [Related]
6. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach.
Moore AS; Norris R; Price G; Nguyen T; Ni M; George R; van Breda K; Duley J; Charles B; Pinkerton R
J Paediatr Child Health; 2011 Dec; 47(12):875-82. PubMed ID: 21658147
[TBL] [Abstract][Full Text] [Related]
7. Vincristine pharmacokinetics in children with Down syndrome.
Lönnerholm G; Frost BM; Söderhäll S; de Graaf SS
Pediatr Blood Cancer; 2009 Jan; 52(1):123-5. PubMed ID: 18615507
[TBL] [Abstract][Full Text] [Related]
8. Decrease in motor performance in children with cancer is independent of the cumulative dose of vincristine.
Hartman A; van den Bos C; Stijnen T; Pieters R
Cancer; 2006 Mar; 106(6):1395-401. PubMed ID: 16453332
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
10. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia.
Plasschaert SL; Groninger E; Boezen M; Kema I; de Vries EG; Uges D; Veerman AJ; Kamps WA; Vellenga E; de Graaf SS; de Bont ES
Clin Pharmacol Ther; 2004 Sep; 76(3):220-9. PubMed ID: 15371983
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study.
Frost BM; Eksborg S; Björk O; Abrahamsson J; Behrendtz M; Castor A; Forestier E; Lönnerholm G
Med Pediatr Oncol; 2002 May; 38(5):329-37. PubMed ID: 11979457
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients.
Bedikian AY; Vardeleon A; Smith T; Campbell S; Namdari R
J Clin Pharmacol; 2006 Jul; 46(7):727-37. PubMed ID: 16809798
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia.
Petersen KB; Jusko WJ; Rasmussen M; Schmiegelow K
Cancer Chemother Pharmacol; 2003 Jun; 51(6):465-73. PubMed ID: 12698270
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection.
Embree L; Gelmon K; Tolcher A; Hudon N; Heggie J; Dedhar C; Logan P; Bally MB; Mayer LD
Cancer Chemother Pharmacol; 1998; 41(5):347-52. PubMed ID: 9523729
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia.
Thomas DA; Sarris AH; Cortes J; Faderl S; O'Brien S; Giles FJ; Garcia-Manero G; Rodriguez MA; Cabanillas F; Kantarjian H
Cancer; 2006 Jan; 106(1):120-7. PubMed ID: 16331634
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
[TBL] [Abstract][Full Text] [Related]
17. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
[TBL] [Abstract][Full Text] [Related]
18. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation.
Lowis SP; Pearson AD; Newell DR; Cole M
Cancer Res; 1993 Oct; 53(20):4881-9. PubMed ID: 8402676
[TBL] [Abstract][Full Text] [Related]
19. Mild axonal neuropathy of children during treatment for acute lymphoblastic leukaemia.
Reinders-Messelink HA; Van Weerden TW; Fock JM; Gidding CE; Vingerhoets HM; Schoemaker MM; Göeken LN; Bökkerink JP; Kamps WA
Eur J Paediatr Neurol; 2000; 4(5):225-33. PubMed ID: 11030069
[TBL] [Abstract][Full Text] [Related]
20. Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients.
Harnicar S; Adel N; Jurcic J
J Oncol Pharm Pract; 2009 Sep; 15(3):175-82. PubMed ID: 19282418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
